| Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study S Zhang, K Tang, G Wan, N Nguyen, C Lu, P Ugwu-Dike, N Raval, J Seo, ... Journal of the American Academy of Dermatology 88 (5), 1024-1032, 2023 | 23 | 2023 |
| Prediction of early-stage melanoma recurrence using clinical and histopathologic features G Wan, N Nguyen, F Liu, MS DeSimone, BW Leung, A Rajeh, MR Collier, ... NPJ precision oncology 6 (1), 79, 2022 | 18 | 2022 |
| Pre-existing autoimmune disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy K Tang, BC Tiu, G Wan, S Zhang, N Nguyen, B Leung, A Gusev, ... Journal of the National Cancer Institute 114 (8), 1200-1202, 2022 | 14 | 2022 |
| Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy N Nguyen, G Wan, P Ugwu-Dike, NA Alexander, N Raval, S Zhang, ... Journal of the American Academy of Dermatology 88 (6), 1308-1316, 2023 | 10 | 2023 |
| Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: a multi-hospital cohort study BW Leung, G Wan, N Nguyen, H Rashdan, S Zhang, W Chen, S Cohen, ... Journal of the American Academy of Dermatology 88 (6), 1265-1270, 2023 | 3 | 2023 |
| Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study G Wan, N Nguyen, BW Leung, H Rashdan, K Tang, K Roster, MR Collier, ... Journal of the American Academy of Dermatology 90 (2), 418-420, 2024 | 2 | 2024 |
| Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: a population-level cohort study BW Leung, MR Collier, BC Tiu, G Wan, N Nguyen, K Tang, S Zhang, ... Journal of the American Academy of Dermatology 88 (5), 1215-1218, 2023 | 2 | 2023 |
| Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study G Wan, S Khattab, BW Leung, S Zhang, N Nguyen, M Tran, C Lin, ... British Journal of Dermatology, ljae053, 2024 | 1 | 2024 |
| Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study H Rashdan, S Zhang, G Wan, N Nguyen, K Roster, A Rajeh, K Tang, ... Journal of the American Academy of Dermatology 90 (5), 1080-1083, 2024 | | 2024 |
| Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study K Roster, A Rajeh, N Nguyen, K Tang, S Zhang, H Rashdan, G Wan, ... Journal of the American Academy of Dermatology 90 (1), 189-192, 2024 | | 2024 |
| 1273 Effect of systemic immunosuppression timing on overall survival among immune checkpoint inhibitor recipients G Wan, N Nguyen, B Yan, M Amadife, BW Leung, K Tang, S Zhang, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 43648 Healthcare Utilization in the 12 Months Following Cutaneous Immune-Related Adverse Events: a Population-Level Cohort Study B Leung, MR Collier, B Tiu, G Wan, N Nguyen, K Tang, S Zhang, W Chen, ... Journal of the American Academy of Dermatology 89 (3), AB52, 2023 | | 2023 |
| LB1686 Impact of dupilumab on survival in patients treated with immune checkpoint inhibitors BW Leung, S Zhang, H Rashdan, G Wan, N Nguyen, N LeBoeuf, ... Journal of Investigative Dermatology 143 (9), B12, 2023 | | 2023 |
| 568 Pre-existing immune-mediated disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study G Wan, N Nguyen, B Leung, H Rashdan, K Tang, M Collier, P Ugwu-Dike, ... Journal of Investigative Dermatology 143 (5), S97, 2023 | | 2023 |
| INCREASED RISK OF CUTANEOUS IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH TALIMOGENE LAHERPAREPVEC AND IMMUNE CHECKPOINT INHIBITORS: A MULTI-INSTITUTIONAL COHORT STUDY B Leung, G Wan, N Nguyen, S Zhang, W Chen, S Cohen, G Boland, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A1316-A1316, 2022 | | 2022 |
| 1268 Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: a multi-institutional cohort … B Leung, G Wan, N Nguyen, S Zhang, W Chen, S Cohen, G Boland, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
